Free Trial
TSE:SVA

Sernova Q2 2023 Earnings Report

Sernova logo
C$0.20 -0.02 (-7.14%)
As of 05/23/2025 03:59 PM Eastern

Sernova EPS Results

Actual EPS
-C$0.03
Consensus EPS
-C$0.02
Beat/Miss
Missed by -C$0.01
One Year Ago EPS
N/A

Sernova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sernova Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Sunday, June 11, 2023
Conference Call Time
6:00PM ET

Earnings Documents

Sernova Earnings Headlines

Stocks in play: Sernova Biotherapeutics
Sernova Biotherapeutics Inc SVA
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Sernova Biotherapeutics Inc (SVA.TO)
See More Sernova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sernova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sernova and other key companies, straight to your email.

About Sernova

Sernova (TSE:SVA) Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.

View Sernova Profile

More Earnings Resources from MarketBeat